硼替佐米联合CHOP方案治疗血管免疫母细胞性T细胞淋巴瘤14例

目的 探讨硼替佐米联合CHOP方案治疗血管免疫母细胞性T细胞淋巴瘤(AITL)的有效性及安全性.方法 14例AITL患者应用硼替佐米(2mg/m2第1天)联合CHOP方案治疗,每21 d为1个疗程,对疗效、安全性及生存情况进行分析.结果 14例患者中初治12例,难治2例.12例患者治疗有效,其中完全缓解6例,部分缓解6例.14例患者3年预计生存率为55％,中位无进展生存时间9.4个月,3年预计无进展生存率为38％.Ⅲ～Ⅳ级中性粒细胞减少(6例)为最常见的血液学毒性;非血液学毒性均为Ⅰ～Ⅱ级,主要包括周围神经毒性(8例),恶心、呕吐(6例),腹泻(4例),感染(4例).结论 硼替佐米联合CHOP方案治疗AITL可在不增加治疗相关不良反应的同时,提高治疗缓解率,改善预后,可用于AITL的诱导及挽救治疗.

Bortezomib in combination with CHOP for 14 patients with angioimmunoblastic T cell lymphoma

Objective To elucidate the curative effects and toxicity of bortezomib in combination with CHOP for patients with angioimmunoblastic T cell lymphoma (AITL).Methods The charts of 14 patients with AITL who received bortezomib 2 mg/m2 d1 plus CHOP regimen were reviewed.Results Among 14 patients including 12 initial and 2 refractory patients, 12 cases got remission (complete remission in 6 cases and partial remission in 6 cases).The anticipated 3-year overall survival rate was 55 ％.The median progression-free survival was 9.4 months.The anticipated 3-year progression-free survival rate was 38 ％.Grade Ⅲ-Ⅳ leucopenia was the most frequent hematological toxicity (6 cases).All of non-hematological toxicities were Ⅰ-Ⅱ grade including peripheral neurotoxicity (8 cases), nauseating and vomiting (6 cases), diarrhea (4 cases) and infection (4 cases).Conclusion The combination of bortezomib and CHOP is an effective and feasible regimen for AITL with acceptable toxicity.